News Release

Researchers develop a risk score to help detect ILD in systemic sclerosis patients

Reports and Proceedings

American College of Rheumatology

ATLANTA — New research presented this week at ACR Convergence 2022, the American College of Rheumatology’s annual meeting, described a first-of-its-kind validated tool to screen for systemic sclerosis-associated interstitial lung disease (Abstract #1526).


Interstitial lung disease (ILD) is a common complication and cause of death in systemic sclerosis (SSc, scleroderma). Although high-resolution computed tomography (HRCT) is the gold standard for diagnosing systemic sclerosis-associated interstitial lung disease (SSc-ILD), not all patients undergo HRCT screening when first diagnosed with systemic sclerosis. It is also unclear when the test should be repeated during follow-up of patients who are negative at baseline. The aim of this research was to develop a risk score for the presence of SSc-ILD (the ILD-RISC score) to guide physicians in ordering baseline and follow-up HRCTs.


“Our previous survey identified that only about 66% of physicians regularly screen for interstitial lung disease with HRCT at the time of systemic sclerosis diagnosis, and this percentage drastically drops to less than 15% during follow-up visits,” explains Cosimo Bruni, MD-PhD, a post-doctoral researcher at the University of Zurich, Research Collaborator at the University of Florence and the study’s lead author. “There are also a certain number of physicians who prefer to be guided by signs, symptoms or other tests to prescribe a chest HRCT. We therefore wanted to create a tool that guides clinicians about HRCTs, both at diagnosis and follow-up.”


The steering board that oversaw the research included six SSc experts, two research fellows and Ilaria Galetti, a patient research partner. They selected 13 variables considered important in the identification of SSc-ILD: sex, age, time from first non-Raynaud’s phenomenon sign or symptom, skin subset, presence of esophageal symptoms, current or past digital ulcers, arthritis, smoking, increased inflammatory markers, New York Heart Association functional class, positive systemic sclerosis autoantibodies, the percent of forced vital capacity (FVC) and diffusing capacity of the lungs for carbon monoxide (DLCO, transfer factor).


The prediction model for ILD was based on baseline visits from systemic sclerosis patients in six European referral centers using multivariable logistic regression with backward selection. Of the 780 included patients, 533 (43% ILD) and 247 (48% ILD) were randomly assigned to the derivation and validation cohorts, respectively. The researchers combined selected laboratory, clinical and pulmonary function features in their statistical model to obtain the ILD-RISC score. They chose a cut-off with 85.6% sensitivity and 53.6% specificity, which was replicated in the validation cohort and applied longitudinally in a cohort of systemic sclerosis patients with negative baseline HRCT.


“It is important to diagnose ILD early in order to start treatment,” Dr. Bruni says. “We still recommend performing HRCT screening in all patients if the test is readily available and patients are willing to undergo it, so as not to miss any patient with ILD. However, in situations where HRCT is not available, or there are patient concerns about HRCT or the physician prefers to order it only in selected patients, our ILD-RISC score supports the ability of HRCT to identify this complication while also helping clinicians avoid HRCT when not indicated. Most important, it may help to decide when to order HRCTs at follow-up, thus limiting unnecessary exams.”


Dr. Bruni notes the score’s relatively low specificity, leading to a certain number of false positives.


“This is a limitation of the current project. We are already working to further improve the score and continue to reduce the number of unnecessary HRCTs,” says Dr. Bruni.


This research was supported by research grants from the Gruppo Italiano Lotta alla Sclerodermia, the New Horizon Fellowship and the Novartis Foundation for Medical-Biological Research. In addition, Dr. Bruni received grants from the European Scleroderma Trial and Research (EUSTAR) group and the Scleroderma Clinical Trial Consortium (SCTC) for other ongoing SSc-ILD projects.


About ACR Convergence

ACR Convergence, the annual meeting of the American College of Rheumatology, is where rheumatology meets to collaborate, celebrate, congregate, and learn. With more than 320 sessions and thousands of abstracts, it offers a superior combination of basic science, clinical science, business education and interactive discussions to improve patient care. For more information about the meeting, visit, or join the conversation on Twitter by following the official hashtag (#ACR22).

About the American College of Rheumatology

Founded in 1934, the American College of Rheumatology (ACR) is a not-for-profit, professional association committed to advancing the specialty of rheumatology that serves nearly 8,500 physicians, health professionals, and scientists worldwide. In doing so, the ACR offers education, research, advocacy and practice management support to help its members continue their innovative work and provide quality patient care. Rheumatology professionals are experts in the diagnosis, management and treatment of more than 100 different types of arthritis and rheumatic diseases. For more information, visit

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.